DH not yet planning to release pandemic stockpile

News

DH not yet planning to release pandemic stockpile

In News

A Government scheme to stockpile essential medicines as a ‘buffer’ against national pandemics still exists in some form - but there are no plans to release any stock as yet, Pharmacy Network News can reveal.

The Department of Health and Social Care told PNN its Essential Medicines Buffer Stockpile (EMBS), originally established in 2010 in the wake of the swine flu pandemic, lapsed in October 2019 without contracts being formally renewed.

However, some manufacturers agreed to extend their contracts on a voluntary basis up to July 2020, and there are currently 142 medicine lines being stockpiled as part of the EMBS, PNN understands.

It is unclear which medicines are currently being kept back. The original scheme, which saw the Department of Health pay manufacturers £80m over five years to house £176m worth of additional stock, covered 454 essential medicines including drugs for epilepsy and schizophrenia, as well as antibiotics and intravenous fluids.

A spokesperson for the DHSC told PNN that the department "continuously reviews the supply situation for all medicines and will consider releases from the EMBS as and when required to manage supply issues and respond to potential increases in demand”.

Gaps in the EMBS were being identified as late as March 2018, when a tender for peritoneal dialysis fluids was issued, covering a period up to the end of March 2020.

In a statement issued last week on measures to support pharmacies tackling the COVID-19 pandemic, the Pharmaceutical Services Negotiating Committee said: "Medicine suppliers have already been approached by Government to assess the impact that COVID-19 could have on the supply chain.

“In particular, DHSC has asked suppliers who still retain some of their EU exit stockpiles to hold onto these. We are talking to DHSC about this."

Previous stockpiling efforts criticised

Government-held buffer stocks have had a chequered history. In 2014 the House of Commons Public Accounts Committee criticised the £560m stockpiling of antivirals oseltamivir (Tamiflu) and zanamivir (Relenza) for use in a flu pandemic on the grounds that there was a lack of consensus over effectiveness.

Some £74m of Tamiflu was written off as a result of poor record keeping by the NHS on how medicines had been stored during the 2009 pandemic. 

Record my learning outcomes

News

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
News

Independent Pharmacy Awards announces finalists

ICP has announced the finalists for the Independent Pharmacy Awards at the House of Commons.

1 Min Article

bookmark_icon_off
News

Bedfordshire Numark pharmacies deliver 68,500 Covid vaccinations

Numark pharmacies worked with six GP surgeries to administer Covid vaccinations in Flitwick

1 Min Article

bookmark_icon_off
News

Children in troubled households more likely to suffer mental health issues

Researchers looked at the anonymised hospital and GP records of 190,000 children in Wales.

1 Min Article

bookmark_icon_off
News

NPA wants competition watchdog to weigh in on hub & spoke

CMA should “look into” hub and spoke dispensing to ensure fairness, says NPA.

1 Min Article

bookmark_icon_off
News

Santander funds multi-million takeover of 11 pharmacies

Santander UK provided twelve and a half million to Aintree-based RB Healthcare.

1 Min Article

bookmark_icon_off
News

RPS urges government to block Philip Morris takeover of respiratory company

Charities and health experts have expressed deep ethical concerns over the deal.

1 Min Article

Recommended Learning

bookmark_icon_off
Sponsored education

Fungal Nail Roundup

Complete this short interactive module to refresh your knowledge on identifying and treating fungal nail infections, and discover more about a product you can recommend to customers.

5 Min Module

bookmark_icon_off
Sponsored education

Relief from the nasal symptoms of allergy

With NHS England advising that OTC products should no longer be prescribed to treat mild-to-moderate hayfever, pharmacy’s role in supporting sufferers is more important than ever. This module includes self-care advice and product recommendations to aid customer conversations.

5 Min Module

bookmark_icon_off
Bayer Business Programme

Let's talk tech: Using technology to drive your business

This training offers insights into making the most of technology and the commercial opportunities this can offer your business.

 

8 Min Module

Sponsored education

Constipation: Making effective recommendations

Learn how to help customers with constipation and find out how even brief conversations can have a positive influence on their health.

15 Min Module

bookmark_icon_off
Sponsored education

Challenge your thinking on warts and verrucas

Discover different treatment options for warts and verruas and when to recommend them to your customers, based on their individual needs

17 Min Module

bookmark_icon_off
Sponsored education

Understanding abdominal pain, cramps and IBS

This short video explains the symptoms of irritable bowel syndrome (IBS) and how it differs from abdominal cramps to help you recommend a suitable product for your customer’s needs.

3 Min Module